These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10177063)

  • 1. Revised diphtheria, tetanus, and pertussis (DTP/DTaP/DT) vaccine information materials--CDC. Notice.
    Fed Regist; 1998 Jan; 63(6):1730-3. PubMed ID: 10177063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New vaccine information materials for hepatitis B, Haemophilus influenzae type b (Hib), and varicella (chickenpox) vaccines, and revised vaccine information materials for measles, mumps, rubella (MMR) vaccines. Centers for Disease Control and Prevention (CDC), Department of Health and Human Services. Notice.
    Fed Regist; 1999 Feb; 64(35):9042-8. PubMed ID: 10557592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed vaccine information materials for hepatitis B, Haemophilus influenzae type b (Hib), Varicella (chickenpox), and measles, mumps, rubella (MMR) vaccines--CDC. Notice with comment period.
    Fed Regist; 1998 Sep; 63(171):47026-31. PubMed ID: 10182707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diphtheria, tetanus, and pertussis: guidelines for vaccine prophylaxis and other preventive measures. Recommendation of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):896-905. PubMed ID: 2998252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events following immunization with DTP vaccine.
    Stetler HC; Mullen JR; Brennan JP; Orenstein WA; Bart KJ; Hinman AR
    Dev Biol Stand; 1985; 61():411-21. PubMed ID: 3879686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
    Taranger J; Trollfors B; Knutsson N
    Dev Biol Stand; 1997; 89():109-12. PubMed ID: 9272340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events following immunization.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1985 Jan; 34(3):43-7. PubMed ID: 2981396
    [No Abstract]   [Full Text] [Related]  

  • 13. Diphtheria, tetanus, and pertussis: Guidelines for vaccine prophylaxis and other preventive measures. Immunization Practices Advisory Committee, Centers for Disease Control.
    Ann Intern Med; 1981 Dec; 95(6):723-8. PubMed ID: 6272621
    [No Abstract]   [Full Text] [Related]  

  • 14. Outbreaks of group A streptococcal abscesses following diphtheria-tetanus toxoid-pertussis vaccination.
    Stetler HC; Garbe PL; Dwyer DM; Facklam RR; Orenstein WA; West GR; Dudley KJ; Bloch AB
    Pediatrics; 1985 Feb; 75(2):299-303. PubMed ID: 3881728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-vaccination symptoms following DTP and DT vaccination.
    Pollock TM; Miller E; Mortimer JY; Smith G
    Dev Biol Stand; 1985; 61():407-10. PubMed ID: 3879685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine.
    Griffin MR; Ray WA; Livengood JR; Schaffner W
    N Engl J Med; 1988 Sep; 319(10):618-23. PubMed ID: 3261837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approval of a second acellular pertussis vaccine for use among infants and young children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Feb; 46(5):110-1. PubMed ID: 9045038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.